Fig. 8: Therapeutic efficacy of MDC against human pancreatic and ovarian cancer.

a Schematic representation of the treatment schedule employed in the in vivo MDC-250 pancreatic study: vehicle control group (PBS control), empty macrophage control group, free HFt-250 drug conjugate control group (at the dose ensuring equivalent 250 drug dose given as MDC-250), free drug control group (250, at the dose ensuring equivalent 250 drug dose given as MDC-250), standard of care group (gemcitabine), treatment group (MDC-250 administered intraperitoneally) and combination group (gemcitabine + MDC-250). Created in BioRender. Taciak, B. (2024) https://BioRender.com/t57p591. b Kaplan–Meier survival curve of mice treated with MDC-250 therapy compared to the control groups. c The statistical significance of the survival was analyzed using the pairwise log-rank tests. d Representative bioluminescence images depicting tumor sizes in mice from the control and MDC-250 treatment groups at various time points. b–d n = 7 mice per group (n = 10 mice in control group) (e) Schematic representation of the treatment schedule employed in the in vivo MDC-735 pancreatic study: vehicle control group (PBS control, intraperitoneal), standard of care group (gemcitabine), treatment group (MDC-735 administered intraperitoneally) and combination group (gemcitabine + MDC-735). Created in BioRender. Taciak, B. (2024) https://BioRender.com/g65f180. f Mean bioluminescence curve of mice treated with MDC-735 therapy compared to the control groups. Data presented as mean ± SEM. g The statistical significance of the bioluminescence signal (end of the study at day 28) was analyzed using the two-way ANOVA with Tukey’s multiple comparisons test. h Representative bioluminescence images depicting tumor sizes in mice from the control and MDC-735 treatment groups measured during the study. e–h n = 8 mice per group. i Schematic representation of the treatment schedule employed in the in vivo MDC-735 ovarian study: vehicle control group (PBS control), standard of care group (paclitaxel), treatment group (MDC-735, administered intraperitoneally). Created in BioRender. Taciak, B. (2025) https://BioRender.com/j88l839. j Mean total bioluminescence (percent of initial value) of SK-OV-3 tumors treated with MDC-735 therapy compared to the control groups at the end of the study. Data presented as mean ± SEM from n = 6 mice per group. k Mean and individual ovary weight (both included) from athymic nude mice orthotopically implanted with SK-OV-3 tumors treated with MDC-735 therapy compared to the control groups. Data presented as mean ± SEM from n = 7 mice in MDC-735 and PBS groups and n = 8 in the Paclitaxel group. j and (k) The one-way ANOVA with Dunnett’s post-hoc test was used for statistical analysis, *P ≤ 0.05, **P ≤ 0.01. l Bioluminescence images depicting tumor sizes in mice from the control and MDC-735 treatment groups at the end of the study. Source data are provided as a Source Data file.